Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma
- 153 Downloads
Intravenous elotuzumab (Empliciti™), a monoclonal antibody targeting the signalling lymphocytic activation molecule F7 (SLAMF7) glycoprotein, is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in previously-treated adult patients. In the pivotal, multinational, phase III ELOQUENT-2 trial in adults with relapsed and/or refractory multiple myeloma, elotuzumab in combination with lenalidomide and dexamethasone significantly prolonged median progression-free survival (PFS) and increased overall response rate (ORR; co-primary endpoints) compared with lenalidomide and dexamethasone alone. The clinical benefit of elotuzumab was maintained over the longer term (≤ 4 years’ minimum follow-up); final overall survival data are awaited. Health-related quality of life was not negatively impacted by the addition of elotuzumab. Elotuzumab combination therapy had a generally manageable tolerability profile and the most common adverse events (AEs) of grade ≥ 3 severity were haematological (e.g. lymphocytopenia, anaemia, thrombocytopenia, neutropenia). Elotuzumab plus lenalidomide and dexamethasone extends the treatment options available for the management of relapsed and/or refractory multiple myeloma.
During the peer review process, the manufacturer of elotuzumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Yvette Lamb is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 6.Bristol-Myers Squibb Pharma EEIG. Empliciti: summary of product characteristics. 2017. http://www.ema.europa.eu/. Accessed 9 Aug 2018.
- 7.Bristol-Myers Squibb Company. Empliciti™ (elotuzumab) for injection, for intravenous use: US prescribing information. 2017. http://packageinserts.bms.com/. Accessed 9 Aug 2018.
- 8.Bristol-Myers Squibb. Humanized anti-human SLAMF 7 monoclonal antibody. Empliciti® for IV infusion: Japanese prescribing information. 2016. http://www.pmda.go.jp/. Accessed 9 Aug 2018.
- 11.Rice AG, Dillon MBC, Van Abbema AM, et al. HuLuc63 in combination regimens with conventional and targeted therapies has additive and synergistic anti-tumour activity in pre-clinical models of myeloma. Blood. 2007;110(11):2517.Google Scholar
- 18.European Medicines Agency. Empliciti: CHMP assessment report. 2016. http://www.ema.europa.eu/. Accessed 9 Aug 2018.
- 20.Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018. https://doi.org/10.1002/cncr.31680.CrossRefPubMedGoogle Scholar
- 23.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma (version 4.2018). 2018. http://www.nccn.org/. Accessed 9 Aug 2018.
- 24.Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;24(Suppl 6):vi133–7.Google Scholar
- 25.Ailawadhi S, DerSarkissian M, Duh MS, et al. Cost offsets in the treatment journeys of patients with relapsed/refractory multiple myeloma (RRMM) [abstract no. 5599]. Blood. 2017;130(Suppl 1):5599.Google Scholar